Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply

Lancet Oncol. 2023 Mar;24(3):e104. doi: 10.1016/S1470-2045(23)00065-7.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aminopyridines
  • Benzimidazoles
  • Breast Neoplasms*
  • Female
  • Humans
  • Immunologic Factors

Substances

  • abemaciclib
  • Aminopyridines
  • Benzimidazoles
  • Immunologic Factors